Congenital Urine Flow Impairment
Conditions
Keywords
congenital urine flow impairment, urinary metabolomics profile, Nuclear Magnetic Resonance
Brief summary
For the new-born, diagnosis and prognosis of congenital urine flow impairment (UFI) are difficult to confirm only with morphological examination (ultrasonography, intravenous pyelography) and functional examination (dynamic renal scan MAG3). Only the test of time allows the post confirmation of a significant UFI requiring a surgery. This meant that the actual therapeutic indications are imperfect by the absence of an absolute endpoint for UFI. The objective of the study is to characterize the urinary metabolomics profile of new born with renal pelvis and/or ureters tract dilatation (suspicion of pelvi-ureteric junction anomalies, primary megaureter and vesico-ureteric reflux), detected by prenatal ultrasonography, by Nuclear Magnetic Resonance (NMR) and metabolomics analysis. This characterization will allow the identification of statistically significant metabolomics markers for the diagnosis and prognosis of a favourable evolution of the anomaly. The evolution with time of these metabolomics profiles will also considered.
Interventions
OTHERLaboratory biomarker analysis on urine sample
Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Months to 3 Months
Healthy volunteers
Yes
Inclusion criteria
* Inclusion Criteria - UFI group: * Newborns or infants between 1 and 3 months of age, * who present an upper urinary tract dilatation detected on prenatal ultrasound scanning, and confirmed with a postnatal sonographic investigation between D4 and D10 of life showing a renal pelvis with an anteroposterior diameter \> 10 mm and/or an ureters \> 6 mm, * Written, informed consent obtained from the 2 parents * Inclusion Criteria - control group: * Newborns or infants between 1 and 3 months of age, * Written, informed consent obtained from the 2 parents * Non-inclusion Criteria - UFI group: * urological associated anomaly: bladder dysfunction, solitary kidney, bilateral pathology, * Absence of parents consent * Non-inclusion Criteria - control group: * Nephrologic or urological anomaly * Previous medical conditions or prior surgery; except minor surgery (inguinal hernia, umbilical hernia, hypertrophic pyloric stenosis…..) * Absence of parents consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| NMR identification of urinary metabolomics markers for diagnosis and prognosis of UFI (suspicion of pelvi-ureteric junction anomalies, primary megaureter and vesico-ureteric reflux) detected in prenatal ultrasonography. | Urine samples of patients will be collected at recruitment time (Day 0). | Urine will be stored at \_80 \_C before acquisition of the NMR data. Urine samples will be thawed at room temperature before use. 400µL of supernatant will be diluted with 200 µL of a buffer solution Na2HPO4/NaH2PO4 (pH = 7.4; 20% D2O/H2O v.v, internal reference: 3-(trimethylsilyl)propionic,2-2-3-3-d4 acid) in Eppendorf tubes. Each sample will be centrifuged for 5 min at 4°C at 12,000 g. Finally, 550 µL will be transferred into 5 mm NMR tubes for analysis. Standard 1H 1D NMR pulse sequences, NOESY and CPMG with water presaturation, will be applied on each sample to obtain corresponding metabolic profiles. In addition, 2D NMR experiments (1H-1H TOCSY or 1H-13C HSQC, and 1H J-Resolved) will be recorded to achieve structural assignment of the metabolic signals. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change of the urinary metabolomics profile change of UFI (pelvi-ureteric junction anomalies, primary megaureter and vesico-ureteric reflux) during the follow-up. | Urine samples of patients will be collected at the follow-up visits between 9 and 12 months of age (M9-M12). | Urine will be stored at \_80 \_C before acquisition of the NMR data. Urine samples will be thawed at room temperature before use. 400µL of supernatant will be diluted with 200 µL of a buffer solution Na2HPO4/NaH2PO4 (pH = 7.4; 20% D2O/H2O v.v, internal reference: 3-(trimethylsilyl)propionic,2-2-3-3-d4 acid) in Eppendorf tubes. Each sample will be centrifuged for 5 min at 4°C at 12,000 g. Finally, 550 µL will be transferred into 5 mm NMR tubes for analysis. Standard 1H 1D NMR pulse sequences, NOESY and CPMG with water presaturation, will be applied on each sample to obtain corresponding metabolic profiles. In addition, 2D NMR experiments (1H-1H TOCSY or 1H-13C HSQC, and 1H J-Resolved) will be recorded to achieve structural assignment of the metabolic signals. |
Countries
France
Outcome results
None listed